Method for optimizing clinical cure rate of chronic hepatitis B
Through screening and phased adjustment of the treatment plans of Peg-IFN-2b and NAs, combined with multiple examinations, the problem of insufficient cure rate of chronic hepatitis B in the prior art was solved, and high HBsAg clearance and functional cure were achieved, which significantly Improved the clinical status of the patient.
Patent Information
- Application Number
- CN202411116733.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively improve the clinical cure rate of chronic hepatitis B, although antiviral drugs such as nucleoside (acid) analogs (NAs) and polyethylene 2 alcohol interferon a (Peg-IFNa) can inhibit HBV replication and alleviate disease Progress, but there are still shortcomings in cure rates.
By screening suitable treatment subjects, using a combination or separate treatment regimen of Peg-IFN-2b and NAs, phased adjustments are performed according to the concentration of HBsAg, and combining multiple tests to optimize treatment strategies, including Peg-IFN-2b dosage and NAs selection. For example, the use of entecavir (ETV) or tenofovir fumarate (TDF) and the treatment plan is adjusted and consolidated according to the HBsAg test results.
The clearance rate of HBsAg was significantly improved, and some patients achieved functional cure, without any signs of later recurrence, significantly alleviating the symptoms of chronic hepatitis B and improving the clinical cure rate.
Smart Images

Figure CN118987176A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of hepatitis B treatment, and more specifically to a method for optimizing the clinical cure rate of chronic hepatitis B. Background Art
[0002] Hepatitis B virus infection, especially chronic hepatitis B virus infection, is one of the most important public health problems in the world. Currently, there are more than 350 million people infected with chronic hepatitis B virus in the world.
[0003] Currently, antiviral drugs used to treat CHB are mainly divided into two categories: nucleoside (acid) analogs (NAs) and pegylated interferon a (Peg-IFNa). With the accumulation of experience in anti-HBV treatment, the treatment goal of long-term inhibition of HBV replication and alleviation of disease progression has been achieved. Hepatitis B patients who have cleared HBsAg have a better prognosis and a significantly reduced risk of HCC after treatment with Peg-IFNa or NAs. If the clinical functional cure rate of chronic hepatitis B can be further optimized, it will be a boon for hepatitis B patients and a great advancement in medicine.
[0004] Therefore, a method to optimize the clinical cure rate of chronic hepatitis B is urgently needed. Summary of the invention
[0005] The technical problem to be solved by the present invention is to provide a method for optimizing the clinical cure rate of chronic hepatitis B to solve the problems in the background technology.
[0006] In order to solve the above technical problems, the technical solutions adopted by the present invention are as follows.
[0007] A method for optimizing the clinical cure rate of chronic hepatitis B specifically comprises the following steps:
[0008] S1. Examine the subjects for treatment, and select those who have received NA treatment for more than 12 months, have HBsAg ≤ 1500 IU / mL, are HBeAg negative, and have HBV DNA < 100 IU / ml as CHB subjects; exclude those who are not suitable for interferon treatment;
[0009] S2. Detect the patient's HBsAg and choose one of the following treatment options for 24 weeks: Peg-IFN-2b + NAs for the entire course, Peg-IFN-2b + NAs for 12 weeks, Peg-IFN-2b + NAs for 24 weeks, or Peg-IFN-2b for 24 weeks;
[0010] S3. Perform HBsAg concentration test. If HBsAg is less than 0.05 IU / mL, the treatment plan for 25-48 weeks is to consolidate the original treatment plan for 12-24 weeks, and recheck at intervals of 12 weeks. The drug should be discontinued after HBsAg is less than 0.05 IU / mL for at least 2 times, and follow-up should be carried out on time; if 0.05 IU / mL ≤ HBsAg < 500 IU / mL, continue the original treatment plan until 48 weeks; if HBsAg ≥ 500 IU / mL, discontinue Peg-IFN-2b and use NAs alone for treatment;
[0011] S4. Perform HBsAg concentration test. If HBsAg is less than 0.05 IU / mL, the treatment plan for 49-72 weeks is to consolidate the original treatment plan for 12-24 weeks, and recheck at intervals of 12 weeks. The drug should be discontinued after HBsAg is less than 0.05 IU / mL for at least 2 times, and follow-up should be carried out on time; if 0.05 IU / mL <= HBsAg < 100 IU / mL, continue the original treatment plan until 72 weeks; if HBsAg ≥ 100 IU / mL, use NAs alone for treatment;
[0012] S5. Perform HBsAg concentration test. If HBsAg is less than 0.05 IU / mL, the treatment plan for 73-96 weeks is predicted to be 12-24 weeks of consolidation treatment with the original plan, with review at intervals of 12 weeks. The drug should be discontinued after HBsAg is less than 0.05 IU / mL for at least 2 times, and follow-up is required on time. If 0.05 IU / mL <= HBsAg, NAs alone will be used for treatment.
[0013] To further optimize the technical plan, the screening items include routine blood tests within the previous 3 months, liver and kidney function tests and fasting blood sugar, hepatitis B two-pair-and-a-half test, hepatitis B virus DNA quantification, hepatitis B surface antigen quantification, thyroid function, serum antinuclear antibodies, urine routine tests, liver color ultrasound, non-invasive liver stiffness tests for those who have the conditions, and electrocardiograms, chest X-rays, and fundus examinations arranged by the attending physician based on the patient's specific circumstances.
[0014] To further optimize the technical solution, the subjects who are not suitable for interferon treatment include: those who are allergic to interferon, those with ALT greater than 10 times the upper limit of normal, total bilirubin greater than 2 times the upper limit of normal, those in the decompensated stage of cirrhosis, or those who have experienced decompensated cirrhosis, those with peripheral blood white blood cell count and / or platelet count below the lower limit of normal, those with serious lesions of important organs such as cardiovascular, lung, kidney, brain and fundus lesions, those with combined autoimmune diseases, mental illness, diabetes, abnormal thyroid function (hyperthyroidism or hypothyroidism), those diagnosed or suspected of liver cancer and other malignant tumors, those who have undergone organ transplantation or are preparing for organ transplantation, those who are using immunosuppressants, those who are pregnant or planning to become pregnant within 2 years, alcoholics or drug addicts, those with HIV infection, and patients who are deemed by the attending physician to have other conditions that are not suitable for the use of interferon.
[0015] The technical solution was further optimized, and the dosage of Peg-IFN-2b was 180 μg or 135 μg each time, subcutaneously injected, once a week; NAs were entecavir (ETV) or tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF).
[0016] Due to the adoption of the above technical scheme, the technical progress achieved by the present invention is as follows.
[0017] The present invention provides a method for optimizing the clinical cure rate of chronic hepatitis B. The method can achieve a higher HBsAg clearance rate or HBsAg serological conversion by screening high-quality treatment subjects and detecting the HBsAg status of the patients in stages during the treatment process, and adjusting the treatment plan for each stage accordingly; the symptoms of chronic hepatitis B are significantly alleviated during the treatment process, and some chronic hepatitis B patients can be functionally cured without signs of late recurrence, thereby optimizing the clinical cure rate of chronic hepatitis B and improving the cure effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 is a flow chart of the present invention;
[0019] Figure 2 It is a multi-branch judgment diagram of the present invention; DETAILED DESCRIPTION
[0020] A method for optimizing the clinical cure rate of chronic hepatitis B, combined with Figures 1 to 2 As shown, the specific steps include:
[0021] S1. Examine the subjects. Screening items include blood routine within the previous 3 months, liver and kidney function and fasting blood sugar, hepatitis B two-to-a-half test, hepatitis B virus DNA quantification, hepatitis B surface antigen quantification, thyroid function, serum antinuclear antibodies, urine routine, liver color Doppler ultrasound, non-invasive liver stiffness test for those who have the conditions, electrocardiogram, chest X-ray and fundus examination arranged by the attending physician according to the specific situation of the patient.
[0022] Patients with CHB who had received NA treatment for more than 12 months, had HBsAg ≤ 1500 IU / mL, were HBeAg negative and had HBV DNA < 100 IU / ml were selected for treatment.
[0023] Subjects who are not suitable for interferon treatment were excluded, including those who are allergic to interferon, those with ALT greater than 10 times the upper limit of normal, total bilirubin greater than 2 times the upper limit of normal, those in the decompensated stage of cirrhosis, or those who have experienced decompensated cirrhosis, those with peripheral blood leukocyte count and / or platelet count below the lower limit of normal, those with serious lesions of important organs such as cardiovascular, lung, kidney, brain and fundus lesions, those with combined autoimmune diseases, mental illness, diabetes, thyroid dysfunction (hyperthyroidism or hypothyroidism), those diagnosed or suspected of liver cancer and other malignant tumors, those who have undergone organ transplantation or are preparing for organ transplantation, those who are using immunosuppressants, those who are pregnant or planning to become pregnant within 2 years, alcoholics or drug addicts, those with HIV infection, and those who are considered by the attending physician to have other conditions that are not suitable for interferon treatment.
[0024] S2. Detect the patient's HBsAg and choose one of the following treatment options: Peg-IFN-2b + NAs combination, Peg-IFN-2b + NAs for 12 weeks, Peg-IFN-2b + NAs for 24 weeks, or Peg-IFN-2b for 24 weeks.
[0025] S3. Perform HBsAg concentration test. If HBsAg is <0.05IU / mL, the 25-48 week treatment plan is to consolidate the original treatment for 12-24 weeks, and review at intervals of 12 weeks. The drug should be discontinued after HBsAg is <0.05IU / mL for at least 2 times, and follow-up should be conducted on time. If 0.05IU / mL<=HBsAg<500IU / mL, continue the original treatment until 48 weeks. If HBsAg≥500IU / mL, discontinue Peg-IFN-2b and use NAs alone for treatment.
[0026] S4. Perform HBsAg concentration test. If HBsAg is less than 0.05 IU / mL, the treatment plan for 49-72 weeks is to consolidate the original treatment for 12-24 weeks, and review at intervals of 12 weeks. The drug should be discontinued after HBsAg is less than 0.05 IU / mL for at least 2 times, and follow-up should be conducted on time. If 0.05 IU / mL <= HBsAg < 100 IU / mL, continue the original treatment until 72 weeks. If HBsAg ≥ 100 IU / mL, use NAs alone for treatment.
[0027] S5. Perform HBsAg concentration test. If HBsAg is less than 0.05 IU / mL, the treatment plan for 73-96 weeks is predicted to be 12-24 weeks of consolidation treatment with the original plan, with review at intervals of 12 weeks. The drug should be discontinued after HBsAg is less than 0.05 IU / mL for at least 2 times, and follow-up is required on time. If 0.05 IU / mL <= HBsAg, NAs alone will be used for treatment.
[0028] In the above steps, the dosage of Peg-IFN-2b is 180 μg or 135 μg each time, subcutaneously injected once a week; NAs are entecavir (ETV) or tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF).
[0029] The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.
[0030] Embodiment 1:
[0031] S1. This patient passed all the screening items, aged 18, male, had been treated with nucleoside (acid) analogs (NAs) for more than 1 year, HBsAg ≤ 1500 IU / mL, HBeAg negative and HBV DNA < 100 IU / ml.
[0032] S2. HBsAg was detected to be 1500 IU / ml, and the 12-week treatment plan of Peg-IFN-2b+NAs was selected. Specifically, after 12 weeks of treatment with Peg-IFNα-2b combined with NAs, NAs were discontinued and Peg-IFNα-2b monotherapy was continued.
[0033] S3. Conduct HBsAg concentration test. If the test result is: HBsAg < 0.05 IU / mL, the treatment plan of 25-48 weeks is to consolidate the original plan for 12-24 weeks, and review it at intervals of 12 weeks. If HBsAg is < 0.05 IU / mL for at least 2 times, stop the medication. The patient is considered to have achieved functional cure and needs to be followed up on time.
[0034] During the follow-up, the patient's various examination results were satisfactory, with no signs of recurrence.
[0035] Embodiment 2:
[0036] S1. This patient passed all the screening items. She was 54 years old, female, had been treated with nucleoside (acid) analogs (NAs) for more than 1 year, HBsAg ≤ 1500 IU / mL, HBeAg negative and HBV DNA < 100 IU / ml.
[0037] S2. HBsAg was detected to be 800 IU / ml, and the 24-week treatment plan of Peg-IFN-2b+NAs was selected. Specifically, after 24 weeks of Peg-IFNα-2b combined with NAs, NAs were discontinued and Peg-IFNα-2b monotherapy was continued.
[0038] S3. Perform HBsAg concentration test. If the test result is: HBsAg ≥ 500 IU / mL, stop using Peg-IFN-2b and use NAs alone for treatment.
[0039] During the follow-up of this patient, the examination results were as follows: HBV serum marker antigen became weakly positive, liver and kidney functions became stronger, and liver elasticity improved.
[0040] Embodiment 3:
[0041] S1. This patient passed all the screening items. He was 35 years old, male, had been treated with nucleoside (acid) analogs (NAs) for more than 1 year, HBsAg ≤ 1500 IU / mL, HBeAg negative and HBV DNA < 100 IU / ml.
[0042] S2. HBsAg was detected to be 600 IU / ml, and the Peg-IFN-2b 24 treatment plan was selected, specifically: full-course Peg-IFNα-2b monotherapy.
[0043] S3. Perform HBsAg concentration test, test result: 0.05IU / mL<=HBsAg<500IU / mL, continue the original treatment plan until 48 weeks.
[0044] S4. Perform HBsAg concentration test, test result: 0.05IU / mL<=HBsAg<100IU / mL, continue the original treatment plan until 72 weeks.
[0045] S5. Conduct HBsAg concentration test. Test result: HBsAg < 0.05 IU / mL. The treatment plan is to consolidate the original plan for 12-24 weeks, and recheck at intervals of 12 weeks. If HBsAg is < 0.05 IU / mL for at least 2 times, stop the medication. The patient is considered to have achieved functional cure and needs to be followed up on time.
[0046] The patient's examination results during follow-up were satisfactory and there was no sign of recurrence.
[0047] Embodiment 4:
[0048] S1. This patient passed all the screening items. He was 30 years old, male, had been treated with nucleoside (acid) analogs (NAs) for more than 1 year, HBsAg ≤ 1500 IU / mL, HBeAg negative and HBV DNA < 100 IU / ml.
[0049] S2. HBsAg was detected to be 1000 IU / ml, and the Peg-IFN-2b+NAs combined treatment plan was selected, specifically: the combined use of NAs and Peg-IFNα-2b throughout the course.
[0050] S3. Perform HBsAg concentration test, test result: 0.05IU / mL<=HBsAg<500IU / mL, continue the original treatment plan until 48 weeks.
[0051] S4. Perform HBsAg concentration test. If the test result is: HBsAg ≥ 100, switch to NAs treatment alone.
[0052] During the follow-up of this patient, the examination results were as follows: HBV serum marker antigen became weakly positive, liver and kidney functions became stronger, and liver elasticity improved.
[0053] Embodiment 5:
[0054] S1. This patient passed all the screening items. She was 28 years old, female, had been treated with nucleoside (acid) analogs (NAs) for more than 1 year, HBsAg ≤ 1500 IU / mL, HBeAg negative and HBV DNA < 100 IU / ml.
[0055] S2, whose HBsAg was detected to be 200 IU / ml, selected the Peg-IFN-2b+NAs 24-week treatment plan, specifically: after 24 weeks of Peg-IFNα-2b combined with NAs, NAs were discontinued and Peg-IFNα-2b monotherapy was continued.
[0056] S3. Perform HBsAg concentration test, test result: 0.05IU / mL<=HBsAg<500IU / mL, continue the original treatment plan until 48 weeks.
[0057] S4. HBsAg concentration test was performed, and the test result was: HBsAg < 0.05 IU / mL. The prediction and display were: the treatment plan of 48-72 weeks is to consolidate the original plan for 12-24 weeks, and recheck at intervals of 12 weeks. If HBsAg is < 0.05 IU / mL for at least 2 times, the medication will be discontinued, which means the patient has achieved functional cure and needs to be followed up on time.
[0058] During the follow-up, the patient's various examination results were satisfactory, with no signs of recurrence.
[0059] According to Examples 1-5, the present method can significantly alleviate the symptoms of chronic hepatitis B, and can even functionally cure some chronic hepatitis B patients without signs of later recurrence, thereby effectively optimizing the clinical cure rate of chronic hepatitis B.
[0060] Functional cure (also called clinical cure) in the present invention refers to sustained virological response after cessation of treatment, disappearance of HBsAg, accompanied by normalization of ALT and improvement of liver tissue lesions.
Claims
1. A method for optimizing the clinical cure rate of chronic hepatitis B, It is characterized in that The specific steps include: S1. Examine the subjects for treatment, and select those who have received NA treatment for more than 12 months, have HBsAg ≤ 1500 IU / mL, are HBeAg negative, and have HBV DNA < 100 IU / ml as CHB subjects; exclude those who are not suitable for interferon treatment; S2. Detect the patient's HBsAg and choose one of the following treatment options for 24 weeks: Peg-IFN-2b + NAs for the entire course, Peg-IFN-2b + NAs for 12 weeks, Peg-IFN-2b + NAs for 24 weeks, or Peg-IFN-2b for 24 weeks; S3. Perform HBsAg concentration test. If HBsAg is less than 0.05 IU / mL, the treatment plan for 25-48 weeks is to consolidate the original treatment plan for 12-24 weeks, and recheck at intervals of 12 weeks. The drug should be discontinued after HBsAg is less than 0.05 IU / mL for at least 2 times, and follow-up should be carried out on time; if 0.05 IU / mL ≤ HBsAg < 500 IU / mL, continue the original treatment plan until 48 weeks; if HBsAg ≥ 500 IU / mL, discontinue Peg-IFN-2b and use NAs alone for treatment; S4. Perform HBsAg concentration test. If HBsAg is less than 0.05 IU / mL, the treatment plan for 49-72 weeks is to consolidate the original treatment plan for 12-24 weeks, and recheck at intervals of 12 weeks. The drug should be discontinued after HBsAg is less than 0.05 IU / mL for at least 2 times, and follow-up should be carried out on time; if 0.05 IU / mL <= HBsAg < 100 IU / mL, continue the original treatment plan until 72 weeks; if HBsAg ≥ 100 IU / mL, use NAs alone for treatment; S5. Perform HBsAg concentration test. If HBsAg is less than 0.05 IU / mL, the treatment plan for 73-96 weeks is predicted to be 12-24 weeks of consolidation treatment with the original plan, with review at intervals of 12 weeks. The drug should be discontinued after HBsAg is less than 0.05 IU / mL for at least 2 times, and follow-up is required on time. If 0.05 IU / mL <= HBsAg, NAs alone will be used for treatment.
2. A method for optimizing the clinical cure rate of chronic hepatitis B according to claim 1, Features: The screening items include routine blood tests within the previous three months, liver and kidney function tests and fasting blood sugar, hepatitis B two-to-a-half test, hepatitis B virus DNA quantification, hepatitis B surface antigen quantification, thyroid function, serum antinuclear antibodies, urine routine tests, liver color ultrasound, non-invasive liver stiffness tests for those who have the conditions, and electrocardiograms, chest X-rays, and fundus examinations arranged by the attending physician based on the patient's specific circumstances.
3. A method for optimizing the clinical cure rate of chronic hepatitis B according to claim 1, It is characterized in that The subjects who are not suitable for interferon treatment include: those who are allergic to interferon, those with ALT greater than 10 times the upper limit of normal, total bilirubin greater than 2 times the upper limit of normal, those in the decompensated stage of cirrhosis, or those who have experienced decompensated cirrhosis, those with peripheral blood white blood cell count and / or platelet count below the lower limit of normal, those with serious lesions of important organs such as cardiovascular, lung, kidney, brain and fundus lesions, those with combined autoimmune diseases, mental illness, diabetes, abnormal thyroid function (hyperthyroidism or hypothyroidism), those diagnosed or suspected of liver cancer and other malignant tumors, those who have undergone organ transplantation or are preparing for organ transplantation, those who are currently using immunosuppressants, those who are pregnant or planning to become pregnant within 2 years, alcoholics or drug addicts, those with HIV infection, and patients with other conditions that the attending physician believes are not suitable for the use of interferon.
4. A method for optimizing the clinical cure rate of chronic hepatitis B according to claim 2, Features: The dosage of Peg-IFN-2b is 180 μg or 135 μg each time, subcutaneously injected once a week; NAs is entecavir (ETV) or tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF).
